AstraZeneca succeeds in treating lupus in late-stage study

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

(Reuters) – AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker’s anifrolumab against rival GlaxoSmithKline Plc’s Benlysta – the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of […]

Continue reading this article with a Fiji Times online membership.

More Stories